CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
|Articles|March 6, 2013
McDonnell, Under Fire From GOP Right, Sends Sebelius Stern Letter on Virginia Medicaid Expansion
Advertisement
RICHMOND, Va. — Under fire from the conservatives in his own Republican Party, Virginia Gov. Bob McDonnell sent the Obama administration a letter Tuesday ruling out Medicaid expansion in the 10 months left in McDonnell’s four-year term.
In the seven-paragraph letter, McDonnell bluntly states to U.S. Health and Human Services Secretary Kathleen Sebelius that the expansion of the federal-state health program for the poor, elderly and disabled is his prerogative, not that of a commission. He also lectures her on shortcomings he sees in the President Barack Obama’s Patient Protection and Affordable Care Act.
Read the full story:
Source: The Washington Post
Advertisement
Related to this article
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Preparing Practices for the Next Era of Hepatitis B Care
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5